BTRX 246040

Drug Profile

BTRX 246040

Alternative Names: BTRX-246040; LY 2940094

Latest Information Update: 12 Nov 2016

Price : $50

At a glance

  • Originator Eli Lilly
  • Developer BlackThorn Therapeutics; Eli Lilly
  • Class Antidepressants; Small molecules
  • Mechanism of Action Nociceptin receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neurological disorders
  • Discontinued Alcoholism; Major depressive disorder

Most Recent Events

  • 20 Oct 2016 Phase-II clinical trials in Neurological disorders in USA (unspecified route)
  • 01 Jun 2014 Eli Lilly completes a phase II trial in Alcoholism in USA (NCT01798303)
  • 31 Mar 2014 Eli Lilly completes a phase II trial for Major depressive disorder in USA (NCT01724112)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top